Showing 1471-1480 of 1697 results for "".
- Researchers Develop Tool That Reliably Predicts Blood Platelet Hyperreactivity and Risk of Strokehttps://practicalneurology.com/news/researchers-develop-tool-that-reliably-predicts-blood-platelet-hyperreactivity-and-risk-of-stroke/2470566/Results of a study published in Nature Communications reveal the association between platelet hyperreactivity and cardiovascular risk in certain patient populations. In their article, the researchers presented a new tool, the Platelet Reactivity ExpreSsion Score (PRESS), which integrates platelet
- Fecal Microbiota Transplantation Had No Benefit as Parkinson Disease Treatmenthttps://practicalneurology.com/news/fecal-microbiota-transplantation-had-no-benefit-as-parkinson-disease-treatment/2470552/Fecal microbiota transplantation (FMT) was associated with alteration in gut microbiota (GMB) but no clinically meaningful improvements in symptoms vs placebo for people with Parkinson disease (PD), according to results of a clinical trial (NCT04854291) sponsored by the Helsinki University Centra
- New PrecivityAD2 Blood Test as Accurate as CSF Biomarker and Amyloid PET Testinghttps://practicalneurology.com/news/p-tau-blood-tests-potentially-provide-greater-accuracy-and-earlier-diagnosis-for-alzheimer-disease/2470539/Two studies presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) suggest that high-performance blood tests are accurate and effective at assessing f
- Buntanetap Treatment for Parkinson Disease Linked to Improvements in Motor, Non-Motor, and Cognitive Functionshttps://practicalneurology.com/news/buntanetap-treatment-for-parkinson-disease-linked-to-improvements-in-motor-non-motor-and-cognitive-functions/2470527/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with improvements in motor and non-motor activities and cognitive functions in p
- Fintepla Reduced Seizures in Those with Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/fintepla-reduced-seizures-in-those-with-developmental-and-epileptic-encephalopathies/2470519/Results of a meta-analysis published in Epilepsia demonstrated that Fintepla (fenfluramine; UCB, Atlanta, GA) treatment was associated with a reduction in the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in individuals with developmental and epile
- Improvements in Cognition, Alzheimer Disease Biomarkers Linked to Novel Small Molecule Drughttps://practicalneurology.com/news/improvements-in-cognition-alzheimer-disease-biomarkers-linked-to-treatment-with-buntanetap/2470512/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with significant improvements in cognition and biomarker measures in people with
- Eplontersen Improves Disease State and QoL in People with Hereditary ATTRv-PNhttps://practicalneurology.com/news/eplontersen-improves-disease-state-and-qol-in-people-with-hereditary-attrv-pn/2470305/In the phase 3 clinical trial NEURO-TTRansform (NCT04136184), treatment with eplontersen (AstraZeneca; Cambridge, UK; Ionis Pharmaceuticals, Carslbad, CA), an investigational ligand-conjugated antisense (LICA) medication that inhibits production of the transthyretin (TTR) protein, was associated
- Potential New Biomarker for CNS Demyelination Identifiedhttps://practicalneurology.com/news/potential-new-biomarker-for-cns-demyelination-identified/2470267/Results from a study recently published in JAMA Neurology identified myelin oligodendrocyte glycoprotein (MOG)-associated immunoglobulin A (IgA) in a small number of patients who were double negative for serum aquapo
- At Home Testing of Neurocognitive Function in People with Alzheimer Disease Shows Potential According to Study from Cumulus Neurosciencehttps://practicalneurology.com/news/at-home-testing-of-neurocognitive-function-in-people-with-alzheimer-disease-shows-potential-according-to-study-from-cumulus-neuroscience/2470255/A presentation at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated the potential for at-home sampling of clinical data for patients with early stages of Alzheimer Disease (A
- Full Results from TRAILBLAZER-ALZ 2 Demonstrate Donanemab Effective at Slowing Cognitive and Functional Decline in Early Alzheimer Diseasehttps://practicalneurology.com/news/new-results-from-trailblazer-alz-2-demonstrate-donanemab-effective-at-slowing-cognitive-and-functional-decline-in-early-alzheimer-disease/2470243/The full results of the phase 3 TRAILBLAZER-ALZ 2 (NCT04437511) study were presented at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC), showing that treatment with donanemab (Eli Lilly